Drug Profile
Research programme: tissue protective cytokines - Takeda
Alternative Names: SPD 500Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Warren Pharmaceuticals
- Class
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic nephropathies; Renal failure
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Oct 2006 Preclinical trials in Diabetic nephropathies in United Kingdom (unspecified route)
- 03 Oct 2006 Preclinical trials in Renal failure in United Kingdom (unspecified route)